Detection and Assessment of Herbal- Drug Interaction Project: SFDA Experience

Author(s)

Alghamdi W1, Alghamdi E1, Al-Fadel N2, Alharbi F2
1Saudi Food and Drug Authority, Riyadh, Saudi Arabia, 2Saudi Food and Drug Authority, Riyadh, 01, Saudi Arabia

Presentation Documents

OBJECTIVES:

There is a general perception of safety and efficacy of herbal medicine compared to conventional medicine. However, limited studies addressed herbal-drug interaction (HDI) in the literature. The Saudi Food and Drug Authority (SFDA) established the HDI Project to detect safety signals related to HDI and assess these signals based on available scientific evidence.

METHODS:

First, a list of SFDA registered herbal products (N=30) were selected and prioritized based on commonly used herbs in Saudi Arabia. Second, reported HDIs were retrieved from the World Health Organization (WHO) global database of individual case safety reports (VigiBase), AdisInsight® and Natural Medicines database. We excluded the interactions of non-registered drugs in Saudi Arabia and labeled interactions in drug and herbal product information, using SFDA, the U.S. Food and Drug Administration and European medicines agency product information. Finally, comprehensive safety evaluation of potential interaction signals were conducted using several evidence sources including literature, results of causality assessment of global cases retrieved from VigiBase and local cases retrieved from the national pharmacovigilance database and other relevant documents. The Drug Interaction Probability Scale (DIPS) was used to assess the probability of a causal relationship between the potential HDI and the events.

RESULTS:

The project yielded 566 potential HDI signals, and 41 interactions had published evidence and referred for extensive evaluation. The assessment results based on DIPS and available evidence were; 24 possibly related (85.5%), 5 probably related (12.1%) and 12 doubtful (29.2%) interactions. The recommendation was to include the probable HDI in the local product information of herbal products and medications include Turmeric-Tacrolimus, Etoposide-Echinacea, Ginkgo Biloba-Ibuprofen, Green Tea-warfarin and Licorice-thiazides interactions.

CONCLUSIONS:

The HDI project in SFDA successfully improved screening and identification of potential drug-herbal interactions. The action plan of this project can be used in post-marketing activities worldwide to identify potential drug interactions.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

RWD138

Topic

Health Policy & Regulatory, Study Approaches

Topic Subcategory

Approval & Labeling, Literature Review & Synthesis

Disease

Alternative Medicine

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×